BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 32166845)

  • 1. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
    Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
    Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
    Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
    Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
    Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
    JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark.
    Lunenburg CATC; Ishtiak-Ahmed K; Werge T; Gasse C
    Pharmacopsychiatry; 2022 Mar; 55(2):95-107. PubMed ID: 34753194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands.
    Bank PCD; Swen JJ; Guchelaar HJ
    BMC Med; 2019 Jun; 17(1):110. PubMed ID: 31196067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings.
    Smith DM; Peshkin BN; Springfield TB; Brown RP; Hwang E; Kmiecik S; Shapiro R; Eldadah Z; Lundergan C; McAlduff J; Levin B; Swain SM
    Clin Transl Sci; 2020 May; 13(3):618-627. PubMed ID: 31961467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
    Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
    Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.
    Bank PCD; Swen JJ; Schaap RD; Klootwijk DB; Baak-Pablo R; Guchelaar HJ
    Eur J Hum Genet; 2019 Oct; 27(10):1532-1541. PubMed ID: 31227807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Pharmacogenetic Drugs by the Dutch Population.
    Alshabeeb MA; Deneer VHM; Khan A; Asselbergs FW
    Front Genet; 2019; 10():567. PubMed ID: 31312209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat prescribing in primary care: a prescription study.
    Saastamoinen L; Enlund H; Klaukka T
    Pharm World Sci; 2008 Oct; 30(5):605-9. PubMed ID: 18509741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic.
    Patel JN; Mueller MK; Guffey WJ; Stegman J
    J Dev Behav Pediatr; 2020 Jan; 41(1):65-70. PubMed ID: 31688658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
    Jablonski MR; Lorenz R; Li J; Dechairo BM
    J Geriatr Psychiatry Neurol; 2020 Nov; 33(6):324-332. PubMed ID: 31842673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
    Alshabeeb MA; Alyabsi M; Paras B
    Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK.
    Youssef E; Kirkdale CL; Wright DJ; Guchelaar HJ; Thornley T
    Br J Clin Pharmacol; 2021 Jul; 87(7):2907-2925. PubMed ID: 33464647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.